720040Novel epinephrine formulationsClosedGRD Development of PrototypeInnovate UKAnaphylaxis occurs in 1 in 3,500 of the UK population and is responsible for around 20 deaths each year. The recommended treatment is injection of epinephrine using an autoinjector such as Epi-pen® or Miniject®. However, around a third of patients suffer a fatal or near-fatal second reaction, termed biphasic anaphylactic reaction. To address this issue, a two dose system (Twinject®) system has been developed that contains 2 doses of epinephrine in the same unit. The main problem with Twinject® is that the second dose must be delivered manually with the same needle. This has increased the complexity of administration (epinephrine is largely administered by care-givers who are not healthcare professionals) and increased the possibility of cross contamination. The alternative to Twinject® is to ensure that the allergy suffers carry two injectors at all times. The epinephrine solution used in the auto-injector has a relatively short shelf life (12- 16m), and the vast majority of the devices are unused at the end of their shelf life. But these devices must be replaced (two a time), which adds significant cost to NHS and other healthcare providers. The aim of this project is to develop an epinephrine product that is simple to use and has a longer shelf life than current products through the delivery of a solid and fast dissolving implant using the Glide Solid Dose Injector (SDI®). The implant is preloaded within a sterile cassette. Just prior to use, the cassette is inserted into the spring powered actuator. It is simple to use and actuated by pressing the device against the skin. The actuator can be re-used many times and two doses of the medication are easily accommodated with a single unit. The cassette is cheap to manufacture. Even if the drug expires, only the cassettes need to be replaced. By use of a solid formulation, the drug stability, hence the shelf life can be significantly improved.